Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a U.S.-based life sciences company built around preparedness for public health threats, with products for opioid overdose, anthrax, smallpox and other emergency-response needs. It also operates a CDMO/Bioservices platform that provides development, manufacturing, fill-finish and packaging services to external biopharma, government and NGO customers.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaNaloxone products sold through retail, prescription and public-health channels.
Anthrax countermeasure products procured mainly for government stockpiles and preparedness.
Smallpox preparedness products sold under government procurement programs.
CDMO services including development, manufacturing, fill-finish and packaging for third parties.
Other legacy products, procured candidates and non-dilutive contract/grant funding.
Tuotteet
Raportoitu · osuus liikevaihdosta- Medical Countermeasures MCM Product61,5 %
- Commercial Product30,4 %
- All Other Revenue8,1 %
Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
The company sells to the U.S. government, foreign governments, and quasi-government/public-health organizations for stockpiling and emergency preparedness. It also serves retail pharmacies, health departments, law enforcement, community organizations and federal agencies for naloxone, plus biopharma companies and NGOs for CDMO services. Demand is driven by public-health readiness, procurement cycles, and the need for specialized manufacturing capacity.
Buys anthrax, smallpox and other countermeasures for the Strategic National Stockpile and preparedness programs.
Retail pharmacies, physician-directed prescriptions and public-health buyers purchase NARCAN and KLOXXADO to address opioid overdose emergencies.
Foreign public-sector customers procure medical countermeasures for national preparedness and response needs.
External developers buy development, drug substance, fill-finish and packaging services to move molecules toward commercialization.
Purchase or fund bioservices and R&D work tied to infectious disease and emergency-response programs.
Strategia
The company is focused on maintaining a portfolio of preparedness products while preserving its role as a supplier to government stockpiles and emergency-response channels. It is also using its integrated CDMO platform to support internal products and external customers, while prioritizing the most commercially and scientifically attractive programs. Portfolio discipline and manufacturing reliability are central to protecting contracts and credibility with public-sector buyers.
A large share of revenue depends on U.S. government stockpile and preparedness buying.
Commercial products diversify the business beyond government procurement cycles.
CDMO services can improve utilization of specialized manufacturing assets and broaden the customer base.
Capital is limited and the company has deprioritized some candidates, so portfolio selection is critical.
Maantiede
2025Emergent is headquartered in the United States and derives most of its business from U.S. government and U.S. commercial channels. Its services footprint includes development and manufacturing sites in the U.S. and Canada, and it also sells countermeasures to customers outside the U.S. Geography matters because procurement, regulatory approval and stockpile demand are highly country-specific, while manufacturing concentration creates operational exposure.
Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.
Riskit
The business is exposed to procurement concentration, especially dependence on U.S. government contracts and funding decisions. It also faces manufacturing, quality and compliance risk because its products and services rely on complex biologics operations, hazardous materials and specialized facilities. Competitive pressure, clinical uncertainty and contract renewal risk can all reduce revenue visibility and margins.
- Manufacturing quality and complianceVaikutus: KorkeaTodennäköisyys: Korkea
Biologics and countermeasure production requires strict controls; failures can trigger recalls, delays or lost contracts.
Kohdistuu: All manufacturing sites and CDMO services
- Facility disruptionVaikutus: KorkeaTodennäköisyys: Korkea
Unplanned outages at development or manufacturing sites can interrupt product supply and bioservices delivery.
Kohdistuu: U.S. and Canada sites
- U.S. government procurement concentrationVaikutus: KorkeaTodennäköisyys: Kohtalainen
The USG is the largest customer, so contract timing or funding changes can materially affect revenue.
Kohdistuu: Anthrax and smallpox MCM products
- Contract renewal and funding riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Existing procurement contracts may not be followed by new awards when they expire.
Kohdistuu: Government MCM portfolio
- Clinical and development uncertaintyVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Product candidates may fail to prove safe, effective or commercially viable.
Kohdistuu: Pipeline programs
Kirjanpito
Harkinnanvaraiset erätLarge procurement deliveries and service milestones can shift revenue between quarters.
Vaikutus: Affects reported sales volatility and comparability
Non-dilutive R&D funding and government contracts may be recognized over time based on performance.
Vaikutus: Affects revenue mix and gross margin
The company uses specialized facilities and has fixed lease obligations.
Vaikutus: Affects balance sheet liabilities and operating expense presentation
Non-cancelable supply commitments can create future cash outflows and inventory risk.
Vaikutus: Affects liquidity and cost structure
Portfolio changes and asset sales require judgment on carrying values and gains/losses.
Vaikutus: Affects reported earnings and asset base
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Rezolute, Inc.
RZLT · Pharmaceutical Preparations
Assembly Biosciences, Inc
ASMB · Pharmaceutical Preparations
Bio Green Med Solution, Inc.
BGMSP · Wholesale-Durable Goods, NEC
Theravance Biopharma, Inc.
TBPH · Pharmaceutical Preparations
Theravance Biopharma is a U.S.-based biopharmaceutical company focused on developing and commercializing medicines for respiratory and other specialty indications.
BioHarvest Sciences Inc
BHST · Pharmaceutical Preparations
NRX Pharmaceuticals, Inc.
NRXP · Pharmaceutical Preparations
Päivitetty: 24.9.2026